Positive
"The expectation for this study, based on our prior clinical experience, is that HA-Irinotecan will provide improved clinical benefit to patients without increasing the burden of toxicity. While it is still early in the trial, the data presented to the DSMB is consistent with that expectation.”
Negative
slow recruitment
- Forums
- ASX - By Stock
- ha-irinotecan phase 3 trial update
Positive"The expectation for this study, based on our prior...
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TSN (ASX) to my watchlist
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable